8-K: Microbot Medical Announces $13 Million Registered Direct Offering

Microbot Medical Inc. has entered into definitive agreements for a $13 million registered direct offering priced at-the-market under Nasdaq rules, along with a concurrent private placement of preferred investment options.

Summary

• Microbot Medical Inc. announced a registered direct offering of 6,103,289 shares of common stock at $2.13 per share, expected to generate approximately $13 million in gross proceeds.
• The offering is priced at-the-market under Nasdaq rules.
• A concurrent private placement will issue unregistered Series I preferred investment options to purchase up to 12,206,578 shares of common stock at an exercise price of $2.13 per share.
• The Series I preferred investment options will be exercisable for two years, beginning after stockholder approval for increasing authorized shares and approving the issuance of shares upon exercise of the warrants.
• The offerings are expected to close around February 11, 2025, pending customary closing conditions.
• H.C. Wainwright & Co. is the exclusive placement agent.
• The company plans to use the net proceeds for continued development, commercialization, and regulatory activities for the LIBERTY Robotic System, expansion and development of additional applications derived from the company's existing IP portfolio, and for working capital and other general corporate purposes.

Sentiment

Score: 6

Explanation: The announcement is neutral to slightly positive. While the capital raise is necessary for the company's growth, it also introduces potential dilution for existing shareholders. The success of the company hinges on the future performance and regulatory approval of its LIBERTY Robotic System.

Positives

• The offering is expected to provide approximately $13 million in gross proceeds to Microbot Medical.
• The funds are earmarked for strategic initiatives, including the development and commercialization of the LIBERTY Robotic System.
• The concurrent private placement provides an opportunity for additional capital if the Series I preferred investment options are exercised.
• The involvement of H.C. Wainwright & Co. as placement agent adds credibility to the offering.

Negatives

• The offering involves the issuance of a significant number of new shares, which could dilute existing shareholders' equity.
• The Series I preferred investment options are unregistered, limiting their immediate tradability.
• The exercise of the Series I preferred investment options is contingent on future stockholder approval.
• The company's plans rely on the successful development and commercialization of the LIBERTY Robotic System, which is subject to regulatory and market risks.

Risks

• The company's plans rely on the successful development and commercialization of the LIBERTY Robotic System, which is subject to regulatory and market risks.
• The exercise of the Series I preferred investment options is contingent on future stockholder approval.
• The company's need for and ability to obtain additional working capital to continue its transition to a commercially focused company.
• Uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will grant 510(k) clearance to commercially market the LIBERTY Endovascular Robotic Surgical System in the United States.
• Disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries.
• Need and ability to obtain future capital, and maintenance of intellectual property rights.

Future Outlook

The company intends to use the net proceeds from the offerings for the continued development, commercialization and regulatory activities for the Company's LIBERTY Robotic System, expansion and development of additional applications derived from the company's existing IP portfolio, and for working capital and other general corporate purposes.

Industry Context

This announcement reflects a common strategy for clinical-stage medical device companies to raise capital to fund ongoing research, development, and commercialization efforts. The at-the-market offering structure provides flexibility in pricing and execution, while the concurrent private placement allows for the issuance of unregistered securities to accredited investors.

Comparison to Industry Standards

• Comparable companies in the medical device space, such as Nano-X Imaging and ReWalk Robotics, have also utilized registered direct offerings and private placements to raise capital.
• The terms of this offering, including the offering price and warrant coverage, are generally consistent with industry standards for similar transactions.
• The intended use of proceeds for product development and commercialization aligns with the typical investment priorities of companies in this sector.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The company's employees and partners may benefit from the increased funding for development and commercialization efforts.
• Customers may benefit from the continued development of the LIBERTY Robotic System.

Next Steps

• The company needs to close the registered direct offering and concurrent private placement.
• The company needs to obtain stockholder approval for increasing authorized shares and approving the issuance of shares upon exercise of the warrants.
• The company needs to continue the development, commercialization, and regulatory activities for the LIBERTY Robotic System.

Key Dates

Keywords

registered direct offering, private placement, preferred investment options, common stock, LIBERTY Robotic System, Microbot Medical, H.C. Wainwright, capital raise, stockholder approval, dilution